

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 19:41:48 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** RE: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Thanks.

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>  
**Sent:** Saturday, February 22, 2020 2:26 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Erbeling, Emily (NIH/NIAID) [E] (b) (6)>  
**Subject:** Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

**From:** "Folkers, Greg (NIH/NIAID) [E]" (b) (6)  
**Date:** February 18, 2020 at 3:07:21 PM EST  
**Subject:** HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

**FOR IMMEDIATE RELEASE**  
**February 18, 2020**  
**Contact: ASPR Press Office**  
**202-205-8117**  
[asprmedia@hhs.gov](mailto:asprmedia@hhs.gov)